UBS/CALL/ROCHE GS/500.004/0.025/19.12.25 Stock

Warrant

CROGTU

CH1147777267

Real-time Bid/Ask 03:32:05 2024-05-17 EDT
0.014 CHF / 0.033 CHF -22.58% Intraday chart for UBS/CALL/ROCHE GS/500.004/0.025/19.12.25
1 month+82.35%
6 months+6.90%
Date Price Change
24-05-14 0.031 -3.12%
24-05-08 0.032 -3.03%

Delayed Quote Swiss Exchange

Last update May 14, 2024 at 11:20 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
CROGTU
ISINCH1147777267
Date issued 2021-12-15
Strike 500 CHF
Maturity 2025-12-19 (582 Days)
Parity 40 : 1
Emission price 0.37 CHF
Emission volume N/A
Settlement physique
Currency CHF

Technical Indicators

Highest since issue 0.45 CHF
Lowest since issue 0.01 CHF
Delta0.03x
Omega 7.623
Premium111.37x
Gearing252.13x
Moneyness 0.4740
Difference Strike 262.7 CHF
Difference Strike %+52.53%
Spread 0.019 CHF
Spread %57.58%
Theoretical value 0.0235
Implied Volatility 29.67 %
Total Loss Probability 98.77 %
Intrinsic value 0.000000
Present value 0.0235
Break even 500.94 CHF
Theta-0x
Vega0.01x
Rho0x

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
234.8 CHF
Average target price
279.4 CHF
Spread / Average Target
+18.99%
Consensus
  1. Stock Market
  2. Warrants
  3. CROGTU Warrant
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW